Jacobs Levy Equity Management
KURA icon

Jacobs Levy Equity Management’s Kura Oncology KURA Stock Holding History

Jacobs Levy Equity Management’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.4M Buy
948,974
+346,743
+58% +$3.27M 0.04% 309
2026
Q1 		$4.9M Sell
602,231
-1,420,102
-70% -$12.2M 0.02% 420
2025
Q4 		$21M Sell
2,022,333
-202,257
-9% -$2.12M 0.08% 199
2025
Q3 		$19.7M Buy
2,224,590
+1,121,228
+102% +$7.99M 0.08% 202
2025
Q2 		$6.37M Sell
1,103,362
-440,751
-29% -$2.7M 0.03% 384
2025
Q1 		$10.2M Buy
1,544,113
+566,193
+58% +$4.41M 0.04% 335
2024
Q4 		$8.52M Buy
+977,920
New +$14.1M 0.03% 330
2020
Q2 		– Sell
-17,602
Closed -$175K – 1103
2020
Q1 		$175K Sell
17,602
-1,660
-9% -$19K ﹤0.01% 906
2019
Q4 		$265K Sell
19,262
-200
-1% -$2.96K ﹤0.01% 882
2019
Q3 		$295K Buy
+19,462
New +$346K ﹤0.01% 778

Other funds holding KURA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

Jacobs Levy Equity Management's KURA Position: Q2 2026 in Review

Jacobs Levy Equity Management increased its Kura Oncology (KURA) stake by 58% in Q2 2026, buying an estimated $3.27M and bringing the position to 948,974 shares worth $10.4M. The position accounts for 0.04% of the portfolio, ranked #309.

Jacobs Levy Equity Management first reported a position in KURA in Q3 2019 and has held it in 10 quarters since. The position peaked at $21M in Q4 2025. 220 funds tracked by Wall St. Rank hold KURA as of Q2 2026.

  • Jacobs Levy Equity Management held 948,974 shares of Kura Oncology worth $10.4M as of Q2 2026.
  • Jacobs Levy Equity Management bought 346,743 Kura Oncology shares in Q2 2026, an estimated $3.27M.
  • Kura Oncology made up 0.04% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #309 holding.
  • Jacobs Levy Equity Management first reported a position in Kura Oncology in Q3 2019 and has held it in 10 quarters since.
  • Jacobs Levy Equity Management's Kura Oncology position peaked at $21M in Q4 2025.
  • 220 funds tracked by Wall St. Rank held Kura Oncology as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.